Crucell N.V. and DSM Biologics have signed a PER.C6 research license agreement with the Taiwan-based AbGenomics Corp. AbGenomics intends to use the PER.C6 cell line for its R&D and early clinical studies of monoclonal antibodies. “The unique characteristics of the PER.C6 technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology’s robustness undoubtedly makes our choice for PER.C6 highly imperative,&#822...